查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1841995

全球先进癌症诊断市场：市场规模、份额和趋势分析（按检测、最终用途和地区划分），细分市场预测（2025-2033 年）

Advanced Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

先进癌症诊断市场摘要

全球先进癌症诊断市场预计在 2024 年达到 583 亿美元，预计到 2033 年将达到 1,270.7 亿美元，2025 年至 2033 年的复合年增长率为 9.05%。

市场受多种强大因素驱动：全球癌症发生率不断上升，持续推动对早期准确检测的需求；及时诊断提高患者生存率，推动基因组学、分子生物学和图像学工具的普及应用。

液态切片、人工智慧病理检测和生物标记伴随诊断等突破性技术正在加速精准肿瘤学的发展，从而实现更个人化和有效的治疗。成本效益也是一个重要的驱动因素，案例研究表明，诊断技术可以透过减少后期治疗和副作用，显着降低医疗成本。同时，不断扩大的报销框架和诸如ECII等大型倡议正在改善患者的可及性和接受度。

先进癌症诊断的市场动态受到快速的技术进步、不断演变的政策框架以及医疗保健重点转变的影响。过去，癌症的诊断和治疗主要依据肿瘤的位置和分期，但先进诊断技术的出现改变了这个模式。这些新工具能够深入了解癌症的分子、遗传和生物学基础，使精准医疗成为现实。透过实现更早、更准确的诊断，先进诊断技术降低了漏诊和误诊的风险，从而为更个人化的治疗方案打开了大门。这种更高的准确性最大限度地减少了患者接受无效治疗及其相关副作用的风险，同时也能即时监测治疗效果。

潜在的益处不仅限于改善病患预后，还能提升医疗体系的效率。整合先进诊断技术的医疗系统可以透过减少无效治疗的需求和最大限度地减少因副作用导致的住院治疗，从而显着降低成本。在爱尔兰的一项案例研究中，对大肠直肠癌患者进行特定基因突变检测，帮助他们避免了严重的副作用，尤其是那些需要住院治疗的副作用，最终为每位患者节省了超过5500万美元。同样，早期发现也能带来显着的成本效益。在乳癌领域，早期诊断已被证明可以降低近50%的医疗成本，与晚期疾病相比，这意味着每个患者群体可节省数亿美元。

科技的应用也能为医疗系统本身节省资源。美国的一项案例研究表明，某学术医疗中心采用数位病理学技术，五年内节省了130万美元，同时提高了诊断准确率，并将诊断审核时间缩短了30%以上。因此，人工智慧的整合正成为重塑工作流程效率和降低错误率的临床和经济催化剂。

同时，推广应用仍面临诸多障碍。先进的诊断技术目前仍局限于研究实验室和专科医院，限制了整个医疗保健系统公平取得这些技术的机会。监管和报销方面的挑战尤其严峻。传统的监管框架并不适用于人工智慧诊断等适应性强的技术，这些技术即使在核准后仍会不断发展。欧盟于2023年启动的TEF-Health倡议获得了近6,600万美元的资金支持，堪称监管创新的案例研究，它提供了一个在监督下测试新方法的沙盒环境。然而，体外诊断医疗设备法规（IVDR）的延迟实施凸显了可能出现瓶颈的风险。分析师估计，多达27,400名癌症患者可能面临临床试验参与延迟，这将导致数亿美元的间接经济损失和治疗费用。

其他资金筹措模式也揭示了潜在效益的规模。澳洲于2016年推出的丙型肝炎报销计划，投入了7.92亿美元，堪称一项开创性的案例研究。该计划预计到2030年将带来41亿美元的生产力提升和38亿美元的净经济效益。将此类模式应用于肿瘤诊断领域，尤其是在液态切片和基因检测等领域，可实现永续的普及和应用。

基础建设也是一大挑战。在许多欧洲医疗系统中，切片检查样本在最终分析前需要经过多个机构，这会延误治疗。在诊断时进行全基因组定序可以简化此流程，但这需要大量投资。数据共用的障碍依然显着。欧洲癌症影像计画（ECII）于2023年启动，已建立了一个价值超过5500万美元的覆盖整个欧洲大陆的癌症影像交换平台，为协作基础设施建设提供了案例研究。这些措施旨在打破资讯孤岛，扩展资料集，并加速诊断创新。

在技​​术方面，英国一项研究表明，液态切片比扫描提前3-5个月检测出復发，每检测100名脑肿瘤患者可节省7200万美元。全身PET影像也取得了类似的进展，其灵敏度提高了40倍，同时缩短了扫描时间并降低了辐射剂量；多参数MRI则使超过25%的疑似前列腺癌患者免于接受侵入性切片检查，相当于每年为整个医疗系统节省数亿美元。

人工智慧正不断整合这些进展。乳癌案例研究表明，人工智慧能够检测高HER2表达并改善患者分层，从而确保更精准的治疗匹配，并带来每年数千万美元的系统级效率提升。与人工审核相比，计算病理学可将分析速度提高高达50%，同时维持或提高准确性。

来自爱尔兰、美国、澳洲和英国的案例研究表明，先进的癌症诊断技术正在展现其临床和经济效益，并从愿景走向实践。然而，在监管、资金、基础设施和公平性方面仍然存在差距。这些动态预示着未来将充满机会与挑战。如果政策制定者和产业领袖能够携手合作，调整法律规范，试点创新融资模式，投资数位化和诊断基础设施，并确保公平应用，那么先进的诊断技术不仅将改变癌症治疗，还将在未来十年重塑医疗保健经济格局。

目录

第一章 分析方法和范围

第二章执行摘要

第三章 市场因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场趋势与展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • PESTEL分析
    • 波特五力分析
  • 新冠疫情影响分析

第四章 透过测试进行业务分析

  • 先进癌症诊断市场：按检测方法分類的波动分析（2024 年和 2033 年）
  • 肿瘤标记检测
    • 肿瘤标记检测市场（2021-2033）
  • 细针穿刺细胞学检查（FNAC）和切片检查
    • 细针穿刺细胞学（FNAC）/切片检查市场（2021-2033）
  • 影像学诊断
    • 诊断影像市场（2021-2033）
  • 骨髓穿刺和切片检查
    • 骨髓穿刺和切片检查市场（2021-2033）
  • 免疫组织化学（IHC）/分子检测
    • 免疫组织化学（IHC）/分子检测市场（2021-2033）
  • 基因检测
    • 基因检测市场（2021-2033）
  • 液态生物检体
    • 液态生物检体市场（2021-2033）

第五章 依最终用途进行业务分析

  • 先进癌症诊断市场：按最终用途分類的趋势分析（2024 年和 2033 年）
  • 医院和癌症中心
    • 医院和癌症中心市场（2021-2033 年）
  • 诊断实验室
    • 诊断实验室市场（2021-2033）
  • 研究和学术机构
    • 研究与学术机构市场（2021-2033）
  • 製药和生物技术公司
    • 医药和生物技术市场（2021-2033）
  • 其他的
    • 其他市场（2021-2033 年）

第六章：区域商业分析

  • 区域市场概况
  • 北美洲
    • 北美高级癌症诊断市场（2021-2033）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲先进癌症诊断市场（2021-2033）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太地区先进癌症诊断市场（2021-2033）
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 拉丁美洲高级癌症诊断市场（2021-2033 年）
    • 主要国家的趋势
    • 法律规范
    • 竞争场景
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲先进癌症诊断市场（2021-2033 年）
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 公司分类
  • 策略规划
    • 企业收购
    • 商业合作
    • 新平台推出
    • 其他的
  • 公司简介/上市公司
    • Fujifilm Holdings Corporation
    • GE Healthcare
    • Siemens Healthineers
    • Philips Healthcare
    • Thermo Fisher Scientific
    • Illumina, Inc.
    • Agilent Technologies
    • Bio-Rad Laboratories
    • Canon Medical Systems
    • Bruker Corporation
    • BD
    • Bio-Rad Laboratories
    • Myriad Genetics
    • Roche Diagnostics
    • F. Hoffmann-La Roche Ltd.

目录

第一章 分析方法和范围

第二章执行摘要

第三章：先进癌症诊断市场：影响因素、趋势与范围

  • 市场关联性展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场趋势与展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • PESTEL分析
    • 波特五力分析
  • 新冠疫情影响分析

第四章 透过测试进行业务分析

  • 先进癌症诊断市场：按检测方法分類的波动分析（2024 年和 2033 年）
  • 肿瘤标记检测
    • 肿瘤标记检测市场（2021-2033）
  • 细针穿刺细胞学检查（FNAC）和切片检查
    • 细针穿刺细胞学（FNAC）/切片检查市场（2021-2033）
  • 影像学诊断
    • 诊断影像市场（2021-2033）
  • 骨髓穿刺和切片检查
    • 骨髓穿刺和切片检查市场（2021-2033）
  • 免疫组织化学（IHC）/分子检测
    • 免疫组织化学（IHC）/分子检测市场（2021-2033）
  • 基因检测
    • 基因检测市场（2021-2033）
  • 液态生物检体
    • 液态生物检体市场（2021-2033）

第五章 依最终用途进行业务分析

  • 先进癌症诊断市场：按最终用途分類的趋势分析（2024 年和 2033 年）
  • 医院和癌症中心
    • 医院和癌症中心市场（2021-2033 年）
  • 诊断实验室
    • 诊断实验室市场（2021-2033）
  • 研究和学术机构
    • 研究与学术机构市场（2021-2033）
  • 製药和生物技术公司
    • 医药和生物技术市场（2021-2033）
  • 其他的
    • 其他市场（2021-2033 年）

第六章：区域商业分析

  • 区域市场概况
  • 北美洲
    • 北美高级癌症诊断市场（2021-2033）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 欧洲先进癌症诊断市场（2021-2033）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 亚太地区先进癌症诊断市场（2021-2033）
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 拉丁美洲高级癌症诊断市场（2021-2033 年）
    • 主要国家的趋势
    • 法律规范
    • 竞争场景
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲先进癌症诊断市场（2021-2033 年）
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 公司分类
  • 策略规划
    • 企业收购
    • 商业合作
    • 新平台推出
    • 其他的
  • 公司简介/上市公司
    • Fujifilm Holdings Corporation
    • GE Healthcare
    • Siemens Healthineers
    • Philips Healthcare
    • Thermo Fisher Scientific
    • Illumina, Inc.
    • Agilent Technologies
    • Bio-Rad Laboratories
    • Canon Medical Systems
    • Bruker Corporation
    • BD
    • Bio-Rad Laboratories
    • Myriad Genetics
    • Roche Diagnostics
    • F. Hoffmann-La Roche Ltd.
Product Code: GVR-4-68040-751-1

Advanced Cancer Diagnostics Market Summary

The global advanced cancer diagnostics market size was estimated at USD 58.30 billion in 2024 and is expected to reach USD 127.07 billion by 2033, expanding at a CAGR of 9.05% from 2025 to 2033. The market is driven by several strong factors. Rising global cancer incidence continues to expand demand for early and precise detection, while patient survival benefits from timely diagnosis are pushing adoption of genomic, molecular, and imaging-based tools.

Breakthroughs such as liquid biopsy, AI-enabled pathology, and biomarker-driven companion diagnostics are accelerating precision oncology, enabling more personalized and effective treatment. Cost-efficiency also acts as a driver, with case studies showing significant healthcare savings when diagnostics reduce late-stage treatments and adverse drug reactions. Alongside this, expanding reimbursement frameworks and large-scale initiatives like ECII are improving access and adoption.

The market dynamics for advanced cancer diagnostics are being shaped by rapid technological progress, evolving policy frameworks, and shifting healthcare priorities. Historically, cancer diagnosis and treatment were guided primarily by tumor location and stage, but the advent of advanced diagnostics has changed this paradigm. These new tools provide granular insights into the molecular, genetic, and biological underpinnings of cancer, making precision medicine a tangible reality. By enabling earlier and more accurate diagnosis, advanced diagnostics reduce the chances of missed or incorrect diagnoses and open the door to more personalized treatment selection. This precision minimizes patient exposure to ineffective therapies and their associated side effects, while also supporting real-time monitoring of treatment effectiveness.

The potential benefits extend beyond patient outcomes to health system efficiency. Health systems that integrate advanced diagnostics could see significant cost savings by reducing the need for ineffective treatments and minimizing hospitalizations from adverse drug reactions. One case study from Ireland illustrates this impact: testing colorectal cancer patients for specific genetic variations generated savings of more than USD 55 million per patient, primarily by avoiding severe side effects that would have required hospital care. Similarly, early detection yields strong cost advantages. In breast cancer, early-stage diagnosis has been shown to reduce medical costs by nearly 50%, equivalent to hundreds of millions of USD per patient cohort when compared with late-stage disease.

Technology adoption can also save resources within the health system itself. A U.S. case study demonstrated that the use of digital pathology at an academic medical center delivered savings of USD 1.3 million over five years, while simultaneously improving accuracy and cutting diagnostic review times by more than 30%. Artificial intelligence integration thus emerges as both a clinical and economic catalyst, reshaping workflow efficiency and lowering error rates.

At the same time, barriers to adoption remain significant. Advanced diagnostics are still largely restricted to research facilities or specialist hospitals, meaning equitable access across wider health systems is limited. Regulatory and reimbursement challenges are particularly acute. Traditional frameworks are not well-suited to adaptive technologies like AI-based diagnostics, which continue to evolve after approval. The EU's TEF-Health initiative, launched in 2023 with funding of nearly USD 66 million, serves as a case study of regulatory innovation, providing a sandbox for real-world testing of new approaches under supervision. Yet, delays tied to the rollout of the In Vitro Diagnostic Medical Devices Regulation (IVDR) highlight the risks of bottlenecks. Analysts estimate that up to 27,400 cancer patients may face delays in clinical trial access, translating into indirect economic and treatment costs of several hundred million USD.

Alternative funding models also reveal the scale of potential benefits. Australia's reimbursement scheme for hepatitis C, introduced in 2016 with funding of USD 792 million, stands as a landmark case study. The program secured projected productivity gains worth USD 4.1 billion and a net economic benefit of USD 3.8 billion by 2030. Applying such models to oncology diagnostics could unlock sustainable access and uptake, particularly in areas like liquid biopsy and genetic testing.

Infrastructure remains another challenge. In many European health systems, biopsy samples still travel across multiple facilities before reaching final analysis, delaying care. Whole-genome sequencing at diagnosis could streamline this process, but requires large-scale investments. Data-sharing barriers also remain critical. The European Cancer Imaging Initiative (ECII), launched in 2023, provides a case study of collaborative infrastructure, establishing a continent-wide platform for cancer image exchange worth more than USD 55 million. Such efforts aim to break down silos, broaden datasets, and accelerate diagnostic innovation.

On the technology front, Liquid biopsy, as demonstrated in a study from England, detected relapse three to five months earlier than scans and saved USD 72 million for every 100 brain tumor patients tested. Similar advances are being seen with total-body PET imaging, which improves sensitivity 40-fold while lowering scan time and radiation dose, and with multiparametric MRI, which has already spared more than 25% of suspected prostate cancer patients from invasive biopsies, amounting to system-level savings in the hundreds of millions of USD annually.

Artificial intelligence continues to unify these advances. A case study in breast cancer demonstrated AI's ability to detect high HER2 expression and improve patient stratification, ensuring better treatment matching and delivering system-level efficiencies worth tens of millions of USD per year. Computational pathology further accelerates analysis by up to 50% compared to manual reviews, while maintaining or improving accuracy.

The advanced cancer diagnostics are moving from promise to practice, with case studies across Ireland, the U.S., Australia, and England proving their clinical and economic impact. Yet, gaps in regulation, funding, infrastructure, and equity remain. These dynamics suggest a future defined by both opportunities and challenges. If policymakers and industry leaders act in tandem adapting regulatory frameworks, piloting innovative funding models, investing in digital and diagnostic infrastructure, and ensuring equitable implementation advanced diagnostics will not only transform cancer care but also reshape healthcare economics across the next decade.

Global Advanced Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For the purpose of this report, Grand View Research has segmented the global advanced cancer diagnostics market report on the basis of test, end use, and region:

  • Test Outlook (Revenue, USD Billion, 2021 - 2033)
  • Tumor Marker Tests
  • Fine Needle Aspiration Cytology (FNAC) & Biopsy
  • Imaging-Based Diagnostics
  • Bone Marrow Aspiration & Biopsy
  • Immunohistochemistry (IHC) & Molecular Testing
  • Genetic Testing for Cancer
  • Liquid Biopsy
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals & Cancer Specialty Centers
  • Diagnostic Laboratories (Independent & Reference Labs)
  • Research & Academic Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Market Definitions
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Cancer Type and End Use Snapshot
  • 2.3. Technique and End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. Porter's Five Forces Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Test Business Analysis

  • 4.1. Advanced Cancer Diagnostics Market: Test Movement Analysis, 2024 & 2033
  • 4.2. Tumor Marker Tests
    • 4.2.1. Tumor Marker Tests Market, 2021 - 2033 (USD Billion)
  • 4.3. Fine Needle Aspiration Cytology (FNAC) & Biopsy
    • 4.3.1. Fine Needle Aspiration Cytology (FNAC) & Biopsy market, 2021 - 2033 (USD Billion)
  • 4.4. Imaging-Based Diagnostics
    • 4.4.1. Imaging-Based Diagnostics market, 2021 - 2033 (USD Billion)
  • 4.5. Bone Marrow Aspiration & Biopsy
    • 4.5.1. Bone Marrow Aspiration & Biopsy market, 2021 - 2033 (USD Billion)
  • 4.6. Immunohistochemistry (IHC) & Molecular Testing
    • 4.6.1. Immunohistochemistry (IHC) & Molecular Testing market, 2021 - 2033 (USD Billion)
  • 4.7. Genetic Testing
    • 4.7.1. Genetic Testing Market, 2021 - 2033 (USD Billion)
  • 4.8. Liquid Biopsy
    • 4.8.1. Liquid Biopsy Market, 2021 - 2033 (USD Billion)

Chapter 5. End Use Business Analysis

  • 5.1. Advanced Cancer Diagnostics Market: End Use Movement Analysis, 2024 & 2033
  • 5.2. Hospitals & Cancer Specialty Centers
    • 5.2.1. Hospitals & Cancer Specialty Centers Market, 2021 - 2033 (USD Billion)
  • 5.3. Diagnostic Laboratories
    • 5.3.1. Diagnostic Laboratories market, 2021 - 2033 (USD Billion)
  • 5.4. Research & Academic Institutes
    • 5.4.1. Research & Academic Institutes market, 2021 - 2033 (USD Billion)
  • 5.5. Pharmaceutical & Biotechnology Companies
    • 5.5.1. Pharmaceutical & Biotechnology Companies market, 2021 - 2033 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Institutes market, 2021 - 2033 (USD Billion)

Chapter 6. Regional Business Analysis

  • 6.1. Regional Market Snapshot
  • 6.2. North America
    • 6.2.1. North America Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.2.2.2. Key Country Dynamics
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. Competitive Scenario
    • 6.2.3. Canada
      • 6.2.3.1. Canada Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.2.3.2. Key Country Dynamics
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Competitive Scenario
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.2.4.2. Key Country Dynamics
      • 6.2.4.3. Regulatory Framework
      • 6.2.4.4. Competitive Scenario
  • 6.3. Europe
    • 6.3.1. Europe Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.3.2. Germany
      • 6.3.2.1. Germany Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.2.2. Key Country Dynamics
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Competitive Scenario
    • 6.3.3. UK
      • 6.3.3.1. UK Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.3.2. Key Country Dynamics
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Competitive Scenario
    • 6.3.4. France
      • 6.3.4.1. France Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.4.2. Key Country Dynamics
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. Competitive Scenario
    • 6.3.5. Italy
      • 6.3.5.1. Italy Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.5.2. Key Country Dynamics
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Competitive Scenario
    • 6.3.6. Spain
      • 6.3.6.1. Spain Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.6.2. Key Country Dynamics
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Competitive Scenario
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.7.2. Key Country Dynamics
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Competitive Scenario
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.8.2. Key Country Dynamics
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Competitive Scenario
    • 6.3.9. Norway
      • 6.3.9.1. Norway Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.3.9.2. Key Country Dynamics
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Competitive Scenario
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.2.2. Key Country Dynamics
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Competitive Scenario
    • 6.4.3. China
      • 6.4.3.1. China Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.3.2. Key Country Dynamics
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Competitive Scenario
    • 6.4.4. India
      • 6.4.4.1. India Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.4.2. Key Country Dynamics
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Competitive Scenario
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.5.2. Key Country Dynamics
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Competitive Scenario
    • 6.4.6. Australia
      • 6.4.6.1. Australia Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.6.2. Key Country Dynamics
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Competitive Scenario
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.4.7.2. Key Country Dynamics
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Competitive Scenario
  • 6.5. Latin America
    • 6.5.1. Latin America Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.5.2. Key Country Dynamics
    • 6.5.3. Regulatory Framework
    • 6.5.4. Competitive Scenario
    • 6.5.5. Brazil
      • 6.5.5.1. Brazil Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.5.5.2. Key Country Dynamics
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Competitive Scenario
    • 6.5.6. Argentina
      • 6.5.6.1. Argentina Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.5.6.2. Key Country Dynamics
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Competitive Scenario
  • 6.6. MEA
    • 6.6.1. MEA Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.6.2.2. Key Country Dynamics
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Competitive Scenario
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.6.3.2. Key Country Dynamics
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Competitive Scenario
    • 6.6.4. UAE
      • 6.6.4.1. UAE Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.6.4.2. Key Country Dynamics
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Competitive Scenario
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Advanced Cancer Diagnostics Market, 2021 - 2033 (USD Billion)
      • 6.6.5.2. Key Country Dynamics
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Competitive Scenario

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
    • 7.2.1. Acquisition
    • 7.2.2. Collaborations
    • 7.2.3. New Platform Launches
    • 7.2.4. Others
  • 7.3. Company Profiles/Listing
    • 7.3.1. Fujifilm Holdings Corporation
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Financial Performance
      • 7.3.1.3. Platform Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. GE Healthcare
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Financial Performance
      • 7.3.2.3. Platform Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. Siemens Healthineers
      • 7.3.3.1. Company Overview
      • 7.3.3.2. Financial Performance
      • 7.3.3.3. Platform Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. Philips Healthcare
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Platform Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Thermo Fisher Scientific
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Platform Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. Illumina, Inc.
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Platform Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. Agilent Technologies
      • 7.3.7.1. Company Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Platform Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Bio-Rad Laboratories
      • 7.3.8.1. Company Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Platform Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. Canon Medical Systems
      • 7.3.9.1. Company Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Platform Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Bruker Corporation
      • 7.3.10.1. Company Overview
      • 7.3.10.2. Financial Performance
      • 7.3.10.3. Platform Benchmarking
      • 7.3.10.4. Strategic Initiatives
    • 7.3.11. BD
      • 7.3.11.1. Company Overview
      • 7.3.11.2. Financial Performance
      • 7.3.11.3. Platform Benchmarking
      • 7.3.11.4. Strategic Initiatives
    • 7.3.12. Bio-Rad Laboratories
      • 7.3.12.1. Company Overview
      • 7.3.12.2. Financial Performance
      • 7.3.12.3. Platform Benchmarking
      • 7.3.12.4. Strategic Initiatives
    • 7.3.13. Myriad Genetics
      • 7.3.13.1. Company Overview
      • 7.3.13.2. Financial Performance
      • 7.3.13.3. Platform Benchmarking
      • 7.3.13.4. Strategic Initiatives
    • 7.3.14. Roche Diagnostics
      • 7.3.14.1. Company Overview
      • 7.3.14.2. Financial Performance
      • 7.3.14.3. Platform Benchmarking
      • 7.3.14.4. Strategic Initiatives
    • 7.3.15. F. Hoffmann-La Roche Ltd.
      • 7.3.15.1. Company Overview
      • 7.3.15.2. Financial Performance
      • 7.3.15.3. Platform Benchmarking
      • 7.3.15.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 4 Global Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 5 Global Advanced Cancer Diagnostics Market, by Region, 2021 - 2033 (USD Billion)
  • Table 6 North America Advanced Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Billion)
  • Table 7 North America Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 8 North America Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 9 U.S Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 10 U.S Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 11 Canada Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 12 Canada Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 13 Mexico Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 14 Mexico Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 15 Europe Advanced Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Billion)
  • Table 16 Europe Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 17 Europe Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 18 UK Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 19 UK Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 20 Germany Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 21 Germany Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 22 France Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 23 France Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 24 Italy Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 25 Italy Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 26 Spain Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 27 Spain Advanced Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Billion)
  • Table 28 Norway Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 29 Norway Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 30 Sweden Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 31 Sweden Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 32 Denmark Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 33 Denmark Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 34 Asia Pacific Advanced Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Billion)
  • Table 35 Asia Pacific Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 36 Asia Pacific Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 37 Japan Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 38 Japan Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 39 China Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 40 China Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 41 India Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 42 India Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 43 Australia Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 44 Australia Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 45 South Korea Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 46 South Korea Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 47 Thailand Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 48 Thailand Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 49 Latin America Advanced Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Billion)
  • Table 50 Latin America Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 51 Latin America Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 52 Brazil Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 53 Brazil Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 54 Argentina Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 55 Argentina Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 56 Middle East Africa Advanced Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Billion)
  • Table 57 Middle East Africa Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 58 Middle East Africa Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 59 South Africa Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 60 South Africa Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 61 Saudi Arabia Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 62 Saudi Arabia Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 63 UAE Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 64 UAE Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)
  • Table 65 Kuwait Advanced Cancer Diagnostics Market, by Test, 2021 - 2033 (USD Billion)
  • Table 66 Kuwait Advanced Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration & Growth Prospect Mapping, 2024
  • Fig. 15 Global Advanced Cancer Diagnostics Market: Test Movement Analysis
  • Fig. 16 Global Tumor Marker Tests Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 17 Global Fine Needle Aspiration Cytology (FNAC) & Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 18 Global Imaging-Based Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 19 Global Bone Marrow Aspiration & Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 20 Global Immunohistochemistry (IHC) & Molecular Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 21 Global Genetic Testing Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 22 Global Liquid Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 23 Global Advanced Cancer Diagnostics Market: End Use Movement Analysis
  • Fig. 24 Global Hospitals & Cancer Specialty Centers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 25 Global Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 26 Global Research & Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 27 Global Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 28 Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 Regional Outlook, 2024 & 2033
  • Fig. 31 Global Advanced Cancer Diagnostics Market: Regional Movement Analysis
  • Fig. 32 North America Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 33 U.S. Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 34 Canada Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 35 Mexico Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 36 Europe Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 37 Germany Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 38 UK Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 39 France Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 40 Italy Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 41 Spain Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 42 Denmark Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 43 Sweden Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 44 Norway Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 45 Asia Pacific Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 46 Japan Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 47 China Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 48 India Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 49 Australia Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 50 South Korea Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 51 Thailand Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 52 Latin America Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 53 Brazil Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 54 Argentina Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 55 Middle East And Africa Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 56 South Africa Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 57 Saudi Arabia Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 58 UAE Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 59 Kuwait Advanced Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)